References
- Tisdale MJ. Pathogenesis of Cancer Cachexia. J Support Oncol 2003; 1: 159-68.
- Inagaki J, Rodriguez V, Bodey GP. Proceedings: causes of death in cancer patients. Cancer 1974; 33: 568-73.
- DeWys WD. Anorexia as a general effect of cancer. Cancer 1972; 45: 2013-19.
- Perboni S, Inui A. Anorexia in cancer: role of feedeing-regulatory peptides. Phil Trans R Soc B 2006; 361: 1281-89.
- Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metas tatic breast cancer. J Clin Oncol 2000; 18: 2395-405.
- Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997; 89: 1763-73.
- Dahele M, Fearon KC. Research methodology: cancer cachexia syndrome. Palliative Medicine 2004; 18: 409-17.
- Bossola M, Muscaritoli M, Costelli P, Bellantone R, Pacelli F, Busquets S, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1 518-23.
- Rossi Fanelli F, Cangiano C, Ceci F, Cellerino R, Franchi F, Menichetti ET, et al. Plasma tryptophan and anorexia in human cancer. Eur J Cancer Clin Oncol 1986; 22: 89-95.
- Padilla GV. Psychological aspects of nutrition and cancer. Surg Clin North Am 1986; 66: 1121-35.
- Knoll J. Endogenous anorectic agents-satietins. Annu Rev Pharmacol Toxicol 1988; 28: 247-68.
- Plata-Salaman CR. Immunoregulators in the nervous system. Neurosci Biobehav 1991; 5: 185-215.
- Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999; 59: 4493-501.
- Inui A. Cancer Anorexia-Cachexia Syndrome: current issues in research and management. CA Cancer J Clin 2000; 52: 72-91.
- Bosaeus I, Daneryd P, Lundholm K. Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 2002; 132 (suppl): S 3465-S 3466.
- Cohn SH, Gartenhaus W, Sawitsky A, Zanzi I, Vaswani A, Ellis KJ. Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabolism 1981; 30: 222-9.
- Knox CS, Crosby CO, Fuerer ID, Buzby GP, Cliffor MD, Mullen JL. Energy expenditure in malnourished cancer patients. Ann Surg 1983; 197: 152-62.
- Nixon DW, Kutner M, Heymsfield S, Foltz AT, Carty C, Seitz S, et al. Resting energy expenditure in lung and colon cancer. Metabolism 1988; 37: 1059-64.
- Fredrix, EW, Soeters PB, Wouters EF, Deerenberg IM, Von-Meyerfeldt MF, Saris WH. Effect of different tumor types on resting energy expenditure. Cancer Res 1991; 51: 6138-41.
- Fredix EW, Saris WH, Soeters PB, Wouters EF, Kester AD, von Meyenfeldt MF, et al. Estimation of body composition by bioelectrical impedance in cancer patients. Eur J Clin Nutr 1990; 44: 749-52.
- Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 325-31.
- Moley JF, Aamodt R, Rumble W, Kaye W, Norton JA. Body cell mass in cancer bearing and anorexia patients. J Parenter Enteral Nutr 1987; 11: 219-22.
- Ohnuma T. Anorexia and cachexia. In: Kufe, Morton, Weichselbaum, editors. Cancer Medicine. Baltimore, MD: Williams & Wilkins; 1997. p. 3091-110.
- Pedersen BK. Exercise immunology. New York: Chapman & Hall; 1997.
- Adams GR, Haddad F. The relationship among IGF-1, DNA content, and protein accumulation during skeletal muscle hypertrophy. J Appl Physiol 1996; 81: 2509-16.
- Richardson RA, Davidson HI. Nutritional demands in acute and chronic illness. Proc Nutr Soc 2003; 62: 777-81.
- Van Miert AS, Kaya F, Van Duin CT. Changes in food intake and forestomach motility of dwarf goats by recombinant bovine cytokines IL-1beta, IL-2 and IFN-gamma. Physiol Behav 1992; 52: 859-64.
- Montuschi P, Tringali G, Curro D, Ciabattoni G, Parente L, Preziosi P, et al. Evidence that IL-1beta and tumor necrosis factor inhibit gastric fundus motility via the 5-lipoxygense pathway. Eur J Pharmacol 1994; 252: 253-60.
- Suto G, Kiraly A, Plourde V, Tache Y. Intravenous IL-1beta induced inhibition of gastric emptying: involvement of central corticotrophin-releasing factor and prostaglandin pathways in rats. Digest 1996; 57: 135-40.
- Suto G, Kiraly A, Tache Y. IL-1b inhibits gastric emptying in rats: mediation through prostaglandin and corticotropin-releasing factor. Gastroenterol 1994; 106: 1568-75.
- Sonti G, Ilyin SE, Plata-Salaman CR. Neuropeptide Y blocks and reverses IL-1b induced anorexia in rats. Peptides 1996; 17: 517-20.
- Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic- pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 1998; 129: 229-40.
- Shimon I, Yan X, Ray DW, Melmed S. Cytokine dependent gp 130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. J Clin Invest 1997; 100: 357-63.
- Argiles JM, Costelli P, Carbo N, Pallares-Trujillo J, Lopez-Soriano FJ. Tumor growth and nitrogen metabolism in the host. Int J Oncol 1999; 14: 479-86.
- Moldawer LL, Andersson C, Gelin J, Lundholm KG. Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol 1988; 254: G 450-6.
- Laviano A, Meguid MM, Yang ZJ, Gleason JR, Cangiano C, Rossi Fanelli F. Cracking the riddle of cancer anorexia. Nutrit 1996; 12: 706-10.
- Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C, Rossi Fanelli F. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med 2000; 48: 40-8.
- Otterness IG, Seymour PA, Golden HW, Reynolds JA, Daumy GO. The effects of continuous administration of murine interleukin-1alpha in the rat. Physiol Behav 1988; 43: 797-804.
- Mrosovsky N, Molony LA, Conn CA, Kluger MJ. Anorexic effects of interleukin in the rat. Am J Physiol 1989; 257: R 1315-21.
- Yasumoto K, Mukaida N, Harada A, Kuno K, Akiyama M, Nakashima E. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma -bearing mice. Cancer Res 1995; 55: 921-7.
- Bodnar RJ, Pasternak GW, Sha P, Stock MJ. Medication of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Cancer Res 1989; 49: 6280-84.
- Kawakami M, Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 1981; 154: 631-7.
- Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vitro. J Clin Invest 1987; 80: 184-90.
- Pape ME, Kim KH. Effect of tumor necrosis factor on acetyl-coenzyme A carboxylase gene expression and pre-adipocyte differentiation. Mol Endocrinol 1988; 2: 395-403.
- Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987; 262: 8390-4.
- Strassmann G, Fong M, Kenny JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681-4.
- Argiles JM, Garcia-Martinez C, Liovera M, Lopez-Soriano FJ. The role of cytokines in muscle wasting: its relation with cancer cachexia. Med Res Rev 1992; 12: 637-52.
- Prelovsek O, Mars T, Jevsek M, Podbregar M, Grubic Z. High dexamethasone concentration prevents stimulatory effects of TNF-alpha and LPS on IL-6 secretion from the precursors of human muscle regeneration. Am J Physiol Regul Integr Comp Physiol. 2006; 291(6): 1651-6.
- Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK. IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 2000; 283(6): 1272-8.
- Llovera M, Lopez-Soriano FJ, Argiles JM. Effects of tumor necrosis factor- on muscle protein turnover in female Wistars rats. J Natl Cancer Inst 1993; 85: 1334-9.
- Darling G, Fraker DL, Jensen JC, Gorschboth CM, Norton JA. Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res 1990; 50: 4008-13.
- Argiles JM, Alvarez B, Lopez - Sorriano FJ. The metabolic basis of cancer cachexia. Med Res Rev 1997; 17: 477-98.
- Bianchi A, Bruce J, Cooper AL, Childs C, Kohli M, Morris ID, et al. Increased brown adipose tissue activity in children with malignant disease. Horm Metab Res 1989; 21: 640-1.
- Strassmann G, Jacob CO, Evans R. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6 mediated cancer cachexia. J Immunol 1992; 148: 3674-8.
- Tsujinaka T, Fujita J, Ebisui C. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996; 97: 244-9.
- Tamura S, Fujimoto-Ouchi K, Mori K, Endo M, Matsumoto T, Eden H, et al. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine carcinoma xenograft. Clin Cancer Res 1995; 1: 1353-8.
- Fearon KC, McMillan DC, Preston T, Winstanley P, Cruickshank AM, Shenkin A. Elevated circulating interleukin-6 is associated with an acute phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 1991; 213: 26-31.
- Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 1994; 205: 182-5.
- Pedersen BK, Febbraio MA. Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6. Physiol Rev 2007; 88: 1379-1406.
- Matthys P, Heremans H, Opdenakker G, Billiau A. Anti-interferon-gamma antibody treatment growth of Lewis lung tumors in mice and tumor-associated cachexia. Eur J Cancer. 1991; 27: 182-7.
- Langstain HN, Doherty GM, Fraker DL, Buresh C, Norton JA. The roles of -interferon and tumor necrosis factor in an experimental rat model of cancer cachexia. Cancer Res 1991; 51: 2302-6.
- Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O, et al. Cancer Cachexia Syndrome Developed in Nude Mice Bearing Melanoma Cells Producing Leukemia-inhibitory Factor. Cancer Res 1991; 51: 6656-9.
- Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumor factor. Br J Cancer 1997; 76: 1035-40.
- Todorov PT, McDevitt TM, Cariuk P, Coles B, Deacon M, Tisdale MJ. Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 1996; 56: 1256-61.
- Hussey HJ, Todorov PT, Field WN, Inagaki N, Tanaka Y, Ishitsuka H, et al. Effect of a fluorinated pyrimidine on cachexia and tumor growth in murine cachexia models: relationship with a proteolysis inducing factor. Br J Cancer 2000; 83: 56-62.
- Cohn SH, Gartenhaus W, Sawitsky A, Rai K, Zani I, Vaswani A, et al. Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, andwater. Metabolism 1981; 30: 222-9.
- Argiles JM, Moore-Carrasco R, Fuster G, Busquets S, Lopez Soriano FJ. Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol 2003; 35: 405-9.
- Mitch WE, Goldberg AL. Mechanisms of skeletal muscle wasting: The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335: 1897-1905.
- Guttridge DC, Mayo MW, Madrid LV, Wang C, Baldwin AS. NF- B-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 298: 2363-7.
- Tisdale MJ. Biomedicine: protein loss in cancer cachexia. Science 2000; 289: 2293-4.
- Spina RJ, Chi MMY, Hopkins MG, Nemeth PM, Lowry OH, Holloszy JO. Mitochondrial enzymes increase in muscle in response to 7-10 days of cycle exercise. J Appl Physiol 1996; 80: 2250-4.
- Al-Majid S, McCarthy DO. Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs 2001; 2: 186-97.
- Diffee GM, Kalfas K, Al-Majid S, McCarthy DO. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol 2002; 283: C 1376-82.
- Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2: 862-71.
- Jurdana M. Radiation effects on skeletal muscle. Radiol Oncol 2008; 42: 15-22.